Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck KGaA/Pfizer's 90 day exclusivity period in effect now

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Nov 21, 2022 10:22pm

147 Views

Post# 35117403

RE:RE:RE:Merck KGaA/Pfizer's 90 day exclusivity period in effect now

Whatever some think Big Pharma will be looking to acquire ONCY so that they can either file for an accelerated approval or 2 Phase 3 studies based on the upcoming BRACELET-1 and GOBLET-1 PFS and OS data. Pharma will want to run and control these registration studies so that they can either obtain approval in 2023 or 2024 at the latest. And based on all of the positive results that is being seen with the clinical trials all this suggests a sooner than expected deal for ONCY even though we keep hearing the mournful howls of barking dogs.

<< Previous

Bullboard Posts

Next >>

The top TSX healthcare stocks under $1